scholarly journals Influence of echocardiographic and radiographic characteristics on atrial sensing amplitude in patients with Linox Smart S DX defibrillation leads

2017 ◽  
Vol 24 (6) ◽  
pp. 671-676 ◽  
Author(s):  
Marcin Michalak ◽  
Andrzej Cacko ◽  
Agnieszka Kapłon-Cieślicka ◽  
Monika Budnik ◽  
Przemysław Stolarz ◽  
...  
Keyword(s):  
Atrial Sensing ◽  
Defibrillation Leads

Lack of atrial sensing from cross-chamber quiet timer blanking in a child with congenital heart disease

Heart Rhythm ◽  
2005 ◽  
Vol 2 (5) ◽  
pp. S253
Author(s):  
Steven M. Yabek ◽  
Lawrence Nair ◽  
William Berman ◽  
Gregg Deutsch
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Atrial Sensing

scholarly journals What do we do about atrial high rate episodes?

2020 ◽  
Vol 22 (Supplement_O) ◽  
pp. O42-O52
Author(s):  
Giuseppe Boriani ◽  
Marco Vitolo ◽  
Jacopo Francesco Imberti ◽  
Tatjana S Potpara ◽  
Gregory Y H Lip
Keyword(s):  
Randomized Clinical Trials ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
High Rate ◽  
Individual Risk ◽  
Cardiac Implantable Electronic Devices ◽  
Net Clinical Benefit ◽  
Embolic Risk ◽  
Atrial Sensing

Abstract Atrial high rate episodes (AHREs) are defined as asymptomatic atrial tachyarrhythmias detected by cardiac implantable electronic devices with atrial sensing, providing automated continuous monitoring and tracings storage, occurring in subjects with no previous clinical atrial fibrillation (AF) and with no AF detected at conventional electrocardiogram recordings. AHREs are associated with an increased thrombo-embolic risk, which is not negligible, although lower than that of clinical AF. The thrombo-embolic risk increases with increasing burden of AHREs, and moreover, AHREs burden shows a dynamic pattern, with tendency to progression along with time, with potential transition to clinical AF. The clinical management of AHREs, in particular with regard to prophylactic treatment with oral anticoagulants (OACs), remains uncertain and heterogeneous. At present, in patients with confirmed AHREs, as a result of device tracing analysis, an integrated, individual and clinically-guided assessment should be applied, taking into account the patients’ risk of stroke (to be reassessed regularly) and the AHREs burden. The use of OACs, preferentially non-vitamin K antagonists OACs, may be justified in selected patients, such as those with longer AHREs durations (in the range of several hours or ≥24 h), with no doubts on AF diagnosis after device tracing analysis and with an estimated high/very high individual risk of stroke, accounting for the anticipated net clinical benefit, and informed patient’s preferences. Two randomized clinical trials on this topic are currently ongoing and are likely to better define the role of anticoagulant therapy in patients with AHREs.

scholarly journals P422New generation cardioverter-defibrillator lead with a floating atrial sensing dipole: strengths and weaknesses during long term performance

EP Europace ◽  
2017 ◽  
Vol 19 (suppl_3) ◽  
pp. iii89-iii90
Author(s):  
ES. Safak ◽  
GDA D`Ancona ◽  
HK. Kaplan ◽  
SK. Kische ◽  
AO. Oener ◽  
...  
Keyword(s):  
Cardioverter Defibrillator ◽  
Defibrillator Lead ◽  
Long Term Performance ◽  
Term Performance ◽  
Atrial Sensing

Retroconduction Selective Recognition in Wide-Dipole Floating Atrial Sensing

1997 ◽  
Vol 20 (11) ◽  
pp. 2817-2824 ◽  
Author(s):  
FRANCO GREGORIO ◽  
MUHAMAD AL-BUNNI ◽  
VINCENZO BULLA ◽  
ADRIANO CROCE ◽  
PIERVITTORIO MORACCHINI ◽  
...  
Keyword(s):  
Selective Recognition ◽  
Atrial Sensing

Removal of Endocardial Defibrillation Leads

1996 ◽  
Vol 19 (1) ◽  
pp. 127-129 ◽  
Author(s):  
LUC JORDAENS ◽  
YVES BELLEGHEM ◽  
LUC HERREGODS
Keyword(s):  
Defibrillation Leads
Sign in / Sign up

Export Citation Format

Share Document